As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to bolster manufacturing of medications that are currently in demand, but it's also thinking about how to better position the company as it pursues development in areas outside of its weight loss pipeline.

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies say this will limit patient access.